Press Releases
Samsung Biologics 2021 Year in Review
2021 was a year to reflect on the decade of immense growth and innovation as we celebrated our 10-year anniversary. We continued with our efforts to supply high-quality biomedicines to patients and embarked upon an important mission to manufacture COVID-19 therapies and mRNA vaccines for both drug product and drug substance to combat the global pandemic to save people’s lives.
As the most trusted CDMO partner to our clients, we have accomplished a number of outstanding achievements and here are some of the key highlights that shaped an extraordinary year.
#TheFutureofBiopharma
At the 2021 JP Morgan Healthcare Conference, we shared our vision for the next decade, unveiling a multi-dimensional business plan for the company with a greater global footprint and continued advancements in future modalities.
By embracing great opportunity ahead of us, we have strived this year to diversify our portfolio to become the global top-tier biopharmaceutical company.
> Samsung Biologics Shares ‘Vision’ for Next Decade at the 39th Annual JP Morgan Healthcare Conference
> John Rim, CEO of Samsung Biologics shares future plans at BIO Digital 2021
> CPhI Worldwide 2021 I Infinite Possibilities for the Next Decade
> Talking COVID-19 Vaccine Cooperation with John Rim
> BBC Storyworks | The Speed of Science
#mRNA
mRNA was without a doubt the most talked about topic this year in turning the tide of the pandemic.
We began the supply of Moderna’s COVID-19 vaccine (mRNA 1273) upon securing the large-scale commercial fill-finish manufacturing agreement and successfully obtained Marketing Authorization from Ministry of Food and Drug Safety of Korea within 7 months of signing.
In November, we also announced the collaboration to manufacture GreenLight’s mRNA COVID-19 vaccine candidate at commercial scale, aiming to open the way to make vaccines available to everybody, including patients in lower income countries.
With our commitment to save lives by creating greater accessibility to biomedicines worldwide, this year we made an announcement to add messenger RNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022.
> Moderna COVID-19 Vaccine Manufactured in Korea by Samsung Biologics Receives Marketing Authorization from Ministry of Food and Drug Safety of Korea
> Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine
> Samsung Biologics to add mRNA vaccine drug substance manufacturing suite to expand portfolio of services
> GreenLight Biosciences and Samsung Biologics announce collaboration to build capacity for messenger RNA Vaccine Manufacturing
#ESG
This year, sustainability was not just a buzzword – it was our mission and commitment.
To create a sustainable future for humanity, we published our first sustainability report, consolidating a roadmap to building a more sustainable environment for all.
In September, we announced the signing of an MOU to participate in the Frontier -1.5D initiative to develop a climate risk management model as part of the 2050 Carbon Neutral Strategy in response to the ongoing challenges associated with global climate change.
We also joined leaders across the healthcare system to form a Health Systems Taskforce as part of the Sustainable Markets Initiative hosted by His Royal Highness Prince of Wales in light of COP26. Within the Taskforce, John Rim, CEO of Samsung Biologics, was designated as a champion for the Supply Chains Working Group with a focus on accelerating the net zero transition across the health system’s supply chains by establishing concrete action plans and metrics to assess its environmental impact.
We are committed to making sustainability a key component of the way we work and engage with our partners and stakeholders, and will continue to actively partake in this global movement next year.
> Samsung Biologics Issues First Annual Sustainability Report
> Sustainable Markets Initiative(SMI) | CEO Message
> Samsung Biologics Joins Frontier 1.5D Project as part of 2050 Carbon Neutral Initiative
> Six Korean companies added to Dow Jones Sustainability World Index
#Quality
Despite the ongoing spread of COVID-19, we established a robust internal system to stably supply biomedicines to patients. Over the course of this year, we added five global ISO certifications for ▲ISO22301 BCMS(Business Continuity Management System▲ISO45001 Occupational Health and Safety ▲ISO14001 Environmental Management ▲ISO50001 Energy Management ▲ISO9001 Quality Management System.
Also amid a time of significant changes to the market dynamics, we proactively implemented innovative digitalized tools into our processes to enhance the client experience. By leveraging our Live Virtual Tour, EQUIS: Enterprise Quality Unified Information System, and virtual exhibition hall, our employees worked tirelessly to improve our service offerings and ultimately provide top-notch quality biomedicines.
> Samsung Biologics Adds Four Global ISO Certifications For BCMS, Energy, Health & Safety, and Environmental Management
> Samsung Biologics adds to global ISO certifications with Quality Management System
> Driven. For Digitalization.
> Samsung Biologics embraces digitalization to provide next-level client satisfaction
#DrivenForLife
In celebration of our 10-year anniversary, we showcased a series of branding films that reinforces our mission to be ‘Driven. For Life.’ At Samsung Biologics, we have a unique business DNA embedded in our employees to make the impossible possible and provide seamless service offerings at an expedited speed to ultimately save lives of patients.
In order to provide speedy delivery of molecules to market, we recently launched our newest CDO process platform, S-CellerateTM that offers complete solution with accelerated speed to IND and BLA. Our teams of experts work relentlessly to contribute to saving lives of people worldwide.
> We are Driven. For Life.
> It’s in our DNA
> Together We Save Lives
> Accelerating your success through our innovative CDO platform | Samsung Biologics premieres S-Cellerate at BPI 2021
> Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021, offering expedited timeline to IND and BLA
Driven. For Life.
In the year 2022, we will continue with our efforts to take on challenges, demonstrate operational excellence across all value chains, and most importantly save the lives of patients.
Related Contents
Samsung BIO Insight The Benefit of Speed, Scale & Quality | Explore Samsung Biologics' CMO Strengths
Samsung BIO Insight The Journey to Your Success | Explore Samsung Biologics' CDO Strengths
2021 was a year to reflect on the decade of immense growth and innovation as we celebrated our 10-year anniversary. We continued with our efforts to supply high-quality biomedicines to patients and embarked upon an important mission to manufacture COVID-19 therapies and mRNA vaccines for both drug product and drug substance to combat the global pandemic to save people’s lives.
As the most trusted CDMO partner to our clients, we have accomplished a number of outstanding achievements and here are some of the key highlights that shaped an extraordinary year.
#TheFutureofBiopharma
At the 2021 JP Morgan Healthcare Conference, we shared our vision for the next decade, unveiling a multi-dimensional business plan for the company with a greater global footprint and continued advancements in future modalities.
By embracing great opportunity ahead of us, we have strived this year to diversify our portfolio to become the global top-tier biopharmaceutical company.
> Samsung Biologics Shares ‘Vision’ for Next Decade
at the 39th Annual JP Morgan Healthcare Conference
> John Rim, CEO of Samsung Biologics shares future
plans at BIO Digital 2021
> CPhI Worldwide 2021 I Infinite Possibilities for
the Next Decade
> Talking COVID-19 Vaccine Cooperation with John
Rim
> BBC Storyworks | The Speed of Science
#mRNA
mRNA was without a doubt the most talked about topic this year in turning the tide of the pandemic.
We began the supply of Moderna’s COVID-19 vaccine (mRNA 1273) upon securing the large-scale commercial fill-finish manufacturing agreement and successfully obtained Marketing Authorization from Ministry of Food and Drug Safety of Korea within 7 months of signing.
In November, we also announced the collaboration to manufacture GreenLight’s mRNA COVID-19 vaccine candidate at commercial scale, aiming to open the way to make vaccines available to everybody, including patients in lower income countries.
With our commitment to save lives by creating greater accessibility to biomedicines worldwide, this year we made an announcement to add messenger RNA vaccine drug substance (DS) manufacturing capability to the current facility in Songdo, ready for cGMP operations within the earlier part of the year in 2022.
> Moderna COVID-19 Vaccine Manufactured in Korea by
Samsung Biologics Receives Marketing Authorization from Ministry of Food and Drug Safety of
Korea
> Moderna and Samsung Biologics Announce Agreement
for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine
> Samsung Biologics to add mRNA vaccine drug
substance manufacturing suite to expand portfolio of services
> GreenLight Biosciences and Samsung Biologics
announce collaboration to build capacity for messenger RNA Vaccine
Manufacturing
#ESG
This year, sustainability was not just a buzzword – it was our mission and commitment.
To create a sustainable future for humanity, we published our first sustainability report, consolidating a roadmap to building a more sustainable environment for all.
In September, we announced the signing of an MOU to participate in the Frontier -1.5D initiative to develop a climate risk management model as part of the 2050 Carbon Neutral Strategy in response to the ongoing challenges associated with global climate change.
We also joined leaders across the healthcare system to form a Health Systems Taskforce as part of the Sustainable Markets Initiative hosted by His Royal Highness Prince of Wales in light of COP26. Within the Taskforce, John Rim, CEO of Samsung Biologics, was designated as a champion for the Supply Chains Working Group with a focus on accelerating the net zero transition across the health system’s supply chains by establishing concrete action plans and metrics to assess its environmental impact.
We are committed to making sustainability a key component of the way we work and engage with our partners and stakeholders, and will continue to actively partake in this global movement next year.
> Samsung Biologics Issues First Annual Sustainability Report
> Sustainable Markets Initiative(SMI) | CEO Message
> Samsung Biologics Joins Frontier 1.5D Project as part of 2050 Carbon Neutral
Initiative
> Six Korean companies added to Dow Jones Sustainability World Index
#Quality
Despite the ongoing spread of COVID-19, we established a robust internal system to stably supply biomedicines to patients. Over the course of this year, we added five global ISO certifications for ▲ISO22301 BCMS(Business Continuity Management System▲ISO45001 Occupational Health and Safety ▲ISO14001 Environmental Management ▲ISO50001 Energy Management ▲ISO9001 Quality Management System.
Also amid a time of significant changes to the market dynamics, we proactively implemented innovative digitalized tools into our processes to enhance the client experience. By leveraging our Live Virtual Tour, EQUIS: Enterprise Quality Unified Information System, and virtual exhibition hall, our employees worked tirelessly to improve our service offerings and ultimately provide top-notch quality biomedicines.
> Samsung Biologics Adds Four Global ISO Certifications For BCMS, Energy, Health &
Safety, and Environmental Management
> Samsung Biologics adds to global ISO certifications with Quality Management
System
> Driven. For Digitalization.
> Samsung Biologics embraces digitalization to provide next-level client
satisfaction
#DrivenForLife
In celebration of our 10-year anniversary, we showcased a series of branding films that reinforces our mission to be ‘Driven. For Life.’ At Samsung Biologics, we have a unique business DNA embedded in our employees to make the impossible possible and provide seamless service offerings at an expedited speed to ultimately save lives of patients.
In order to provide speedy delivery of molecules to market, we recently launched our newest CDO process platform, S-CellerateTM that offers complete solution with accelerated speed to IND and BLA. Our teams of experts work relentlessly to contribute to saving lives of people worldwide.
> We are Driven. For Life.
> It’s in our DNA
> Together We Save Lives
> Accelerating your success through our innovative CDO platform | Samsung Biologics
premieres S-Cellerate at BPI 2021
> Samsung Biologics showcases its newest CDO process platform, S-Cellerate™, at BPI 2021,
offering expedited timeline to IND and BLA
Driven. For Life.
In the year 2022, we will continue with our efforts to take on challenges, demonstrate operational excellence across all value chains, and most importantly save the lives of patients.
Related Contents
Samsung BIO Insight The Benefit of Speed, Scale & Quality | Explore Samsung Biologics' CMO Strengths
Samsung BIO Insight The Journey to Your Success | Explore Samsung Biologics' CDO Strengths